CDC alert on ricin ; FDA and CDC statement concerning rumors about recalled lot of influenza vaccine
HAN	; 158
Centers for Disease Control and Prevention (U.S.)	. United States. Food and Drug Administration.	.
Centers for Disease Control and Prevention (U.S.)	. United States. Food and Drug Administration.	Less ▲
Drug Contamination
Influenza Vaccines/standards
Ricin/poisoning
Friday, October 17, 2003, 19:00 EDT (07:00 PM EDT)
CDCHAN-00158-03-10-17-UPD–N
The United States Postal Service, in conjunction with federal and state law enforcement and public health officials, identified an unmarked and sealed envelope containing a threatening note and a sealed container believed to contain a toxic substance at a small postal handling facility in Greenville, South Carolina. The Department of Health and Human Services' Centers for Disease Control and Prevention (CDC) confirmed that the substance was the toxin Ricin.
The facility was closed and CDC conducted environmental testing. The results of the environmental testing were negative for the presence of Ricin. There are no indications of employee exposure or of adverse health effects as a result of this incident. A criminal investigation by the FBI and US Postal Inspection Service is currently underway.
Ricin is a potent biologic toxin that is derived from castor beans. Inhalation of Ricin or of abrin, which is a closely related toxin, typically leads to cough and respiratory distress followed by pulmonary edema, respiratory failure, and multisystem organ failure. Weakness and influenza-like symptoms of fever, myalgia, and arthralgia may also be reported.
For an overview of Ricin, including signs, symptoms, and treatment, please visit http://www.bt.cdc.gov/agent/ricin/index.asp.
Anyone needing more information on Ricin poisoning should contact a local poison control center.
Clinicians who suspect cases of Ricin poisoning are requested to immediately report such cases to their state or local health departments.
FDA and CDC Statement Concerning Rumors about Recalled Lot of Influenza Vaccine
Rumors have been circulating that a "contaminated" lot of flu vaccine has been recalled by the FDA. This is false. No contamination of any flu vaccine has been identified anywhere in the U.S., and the FDA has not recalled any lot of flu vaccine. Flu vaccine is routinely tested for safety, purity, and potency and all lots released have met these standards. As with any vaccine, flu vaccine is capable of causing some side effects, these are very rarely severe. Most side effects from flu vaccine are mild, such as arm soreness, redness or swelling where the shot was given, fever, or achiness. More serious reactions to the flu vaccine do occur, but they are rare. While FDA and CDC are currently investigating several recent reports of possible significant allergic reactions to flu vaccine, it is important to note that the number and type of reactions reported to date are not unexpected. The reactions reported, not all of which may have been caused by the administration of vaccine, do not, at this time, suggest any problem with the flu vaccine. However, FDA and CDC will continue to investigate these and any other reports and will provide any further information as available. While serious reactions to flu vaccine are rare, each year about 114,000 people in the U.S. are hospitalized and about 36,000 people die because of the flu. The flu vaccine is the best way a person can protect themselves and their loved ones against influenza. October and November are the best months to get vaccinated - however, vaccination in December or later still provides considerable protection. For more information about influenza, go to http://www.cdc.gov/nip/Flu.
HAN Health Advisory
Health Alert Network (HAN)
urn:sha256:ee859d106669938629b3fbff2f9a2bedee7cf2edfcb6ff516291202d3f852070
First National Symposium on Medical and Public Health Response to Bioterrorism
Henderson, Donald A. (Donald Ainslie), 1928-2016.; Shalala, Donna E.; Hughes, James M.; McCann, S. Anthony; Clarke, Richard A.; Tucker, Jonathan B.; Siegrist, David W.; Davis, Christopher J.; Olson, Kyle B.; Stern, Jessica; Kortepeter , Mark G.; Parker, Gerald W.; Pavlin, Julie A.; Russell, Philip K.; Zoon, Kathryn C.; O'Toole, Tara; Jason Bardi; Cieslak, Theodore J.; Eitzen, Edward M.; Inglesby, Thomas V.; Bartlett, John G.; Hamburg, Margaret A.;
National Center for Infectious Diseases (U.S.)
National Symposium on Medical and Public Health Response to Bioterrorism (1999 : Baltimore, MD)
July–August 1999
Emerginc infectious diseases ; v. 5, no. 4, p. 491-565
On February 16-17, 1999, in Arlington, Virginia, 950 public health officials, physicians, and other medical personnel, along with government, military, and intelligence experts gathered for the first National Symposium on Medical and Public Health Re...
Summary report : May 1-2, 2012 : Board of Scientific Counselors (BSC), Office of Public Health Preparedness and Response (OPHPR), Centers for Disease Control and Prevention (CDC)
Centers for Disease Control and Prevention (U.S). Office of Public Health Preparedness and Response. Board of Scientific Counselors.
Welcome and Introductions -- Review of Federal Advisory Committee Act (FACA) Conflict of Interest Issues -- Review of Updates to OPHPR Responses to BSC Work Group Reports and Recommendations -- Laboratory Preparedness: CDC Science and Practice -- Pro...
MedImmune Monovalent 2009 (H1N1) influenza nasal spray vaccine - shortened shelf life of certain lots
HAN ; 304
Wednesday, December 23, 2009, 09:20 EST (9:20 AM EST) : CDCHAN-00304-2009-12-23-UPD-N : MedImmune announces limited, voluntary, non-safety-related recall o f remaining unused product. : On December 18 and 21, MedImmune notified CDC and FDA that the p...
Clinical laboratory preparedness and response guide
Association of Public Health Laboratories (U.S.). American Society for Microbiology.. Centers for Disease Control and Prevention (U.S.).
DATE: Version 1.1: Revision date: 11/16/2016 : Hospital and clinical laboratories are the first line of defense against biothreat agent infections and emerging infectious diseases. These laboratories will likely be the first to see clinical specimens...
Manufacturer's recall of human rabies vaccine
Friday, April 02, 2004, 23:11 EST (11:11 PM EST) : CDCHAN-00194-2004-04-02-ADV-N : CDC and the Food and Drug Administration (FDA) have been notified that a recent quality-assurance test of IMOVAX® Rabies Vaccine (Aventis Pasteur, Swiftwater, Pennsyl...